Technical Data
N2050-10K
Nerve Growth Factor, beta, Recombinant, Human (Beta-nerve Growth Factor, Beta-NGF, NGFb, NGF, HSAN5, MGC161426, MGC161428)
5ug
|
Technical Data |
|
N2050-10K |
Nerve Growth Factor, beta, Recombinant, Human (Beta-nerve Growth Factor, Beta-NGF, NGFb, NGF, HSAN5, MGC161426, MGC161428) |
5ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
Source: Recombinant corresponding to 119aa of human beta-Nerve Growth Factor expressed in E.coli is a homodimer, glycosylated, polypeptide chain. Molecular Weight: ~17kD Biological Activity: The ED50,calculated by its ability to stimulate chick E9 DRG neurite outgrowth was found to be 1x106 units/mg. Dimmers and Aggregates: 1% (SDS-PAGE) Protein Content: Protein quantitation was carried out by two independent methods:1.UV spectroscopy at 280nm using the absorbency value of 1.1945 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of Recombinant corresponding to beta-Nerve Growth Factor as a Reference Standard. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: ~17kD |
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug) Concentration: Not determined Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. The statistical mechanics of complex signaling networks: nerve growth factor signaling.Phys Biol 2004 Dec;1(3-4):184-95. 2. Intraventricular nerve growth factor infusion: a possible treatment for neurological deficits following hypoxic-ischemic brain injury in infants. Neurol Res 2005 Oct;27(7):741-6. 3. Nerve growth factor-induced expression of the GTP cyclohydrolase I gene via Ras/MEK pathway in PC12D cells. J Neurochem 2005 Oct;95(2):563-9. 4. Spatio-temporal activation of cyclic AMP response element-binding protein, activity-regulated cytoskeletal-associated protein and brain-derived nerve growth factor: a mechanism for pontine-wave generator activation-dependent two-way active-avoidance memory processing in the rat. J Neurochem 2005 Oct;95(2):418-28. 5. Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats. Invest Ophthalmol Vis Sci 2005 Oct;46(10):3800-6. 6. Nerve growth factor mediates its pro-invasive effect in parallel with the release of a soluble E-cadherin fragment from breast cancer MCF-7/AZ cells. J Dairy Res 2005;72 Spec No:20-6.
|
||